title: [The results of adjuvant therapy of juvenile recurring respiratory papillomatosis with the use of indole-3-carbinol].
abstract: The authors analyse the efficacy of anti-relapse therapy of juvenile recurring respiratory papillomatosis in 87 children aged from 2 to 15 years with the use of indole-3-carbinol. Prior to inclusion into this study, the patients underwent from 2 to 86 (mean 12 +/- 14) surgical interventions for the ablation of papillomas. The average interval between successive relapses of papillomas ranged between 2 weeks and 12 months (mean 4.9 +/- 2.33 months). The patients remained under observation in the clinic during 2 years--6 years 5 months (mean 44.8 +/- 15.93 months). The duration of therapy with indole-3-carbinol varied from 12 weeks to 2 years (mean 8.9 +/- 4.72 months). The stable remission of pathology was documented in 28.7% of the patients within the 2 to 6 year follow-up period. A significant (1.5-10-fold) increase in the duration of interval between successive relapses occurred in 41.1% of the children. In 29.9% of the patients, therapy produced no apparent clinical effect; 18.4% of them showed an insignificant shortening of the interval between relapses that remained unaltered in the remaining 11.5%. No adverse effects of the treatment were recorded. It is concluded that treatment with indole-3-carbinol can be recommended as a starting therapeutic modality for the management of juvenile recurring respiratory papillomatosis and the reduction of the intervals between relapses of the disease.
authors.forename: Iu L
authors.initials: IuL
authors.lastname: Soldatskiĭ
authors.forename: E K
authors.initials: EK
authors.lastname: Onufrieva
authors.forename: A M
authors.initials: AM
authors.lastname: Steklov
authors.forename: S F
authors.initials: SF
authors.lastname: Gasparian
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Strygina
mesh_terms: D000293:Adolescent; D016588:Anticarcinogenic Agents / Q000008:administration & dosage / Q000009:adverse effects; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects; D007828:Laryngoscopy / Q000379:methods*; D008297:Male; D030361:Papillomavirus Infections / Q000473:pathology / Q000628:therapy*; D013510:Pulmonary Surgical Procedures / Q000379:methods*; D012137:Respiratory System / Q000601:surgery*; D012141:Respiratory Tract Infections / Q000473:pathology / Q000628:therapy*; D055502:Secondary Prevention; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D016588:Anticarcinogenic Agents; D007211:Indoles; C016517:indole-3-carbinol